Abstract
Simple SummaryThe treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics and the recognition of targetable oncogenic driver alterations. This has led to the development of very effective new targeted agents, and thus to a relevant progress in the treatment of oncogene-addicted NSCLC. While the treatment of EGFR-mutated and ALK-rearranged NSCLC is well-established, new targeted therapy options have emerged for other oncogenic alterations. In this comprehensive review article, we discuss the major molecular alterations in NSCLC and the corresponding therapeutic options.Due to groundbreaking developments and continuous progress, the treatment of advanced and metastatic non-small cell lung cancer (NSCLC) has become an exciting, but increasingly challenging task. This applies, in particular, to the subgroup of NSCLC with oncogenic driver alterations. While the treatment of epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged NSCLC with various tyrosine kinase inhibitors (TKIs) is well-established, new targets have been identified in the last few years and new TKIs introduced in clinical practice. Even for KRAS mutations, considered for a long time as an “un-targetable” alteration, promising new drugs are emerging. The detection and in-depth molecular analysis of resistance mechanisms has further fueled the development of new therapeutic strategies. The objective of this review is to give a comprehensive overview on the current landscape of targetable oncogenic alterations in NSCLC.
Highlights
Lung cancer is by far the leading cause of cancer-related mortality in both male and female worldwide, accounting for nearly 20% of all cancer deaths in Europe [1].Most represent non-small cell lung cancer (NSCLC, 85%) with adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell neuroendocrine carcinoma (LCNEC) being the most common morphological subtypes [2]
The present review provides an overview on targeted therapy options in advanced and metastatic NSCLC with oncogenic driver alterations
Within the Swiss Group for Clinical Cancer Research (SAKK) network, we have investigated the combination of the MEK-inhibitor binimetinib with cisplatin/pemetrexed as first-line therapy in a phase I/II study
Summary
Lung cancer is by far the leading cause of cancer-related mortality in both male and female worldwide, accounting for nearly 20% of all cancer deaths in Europe [1]. Most represent non-small cell lung cancer (NSCLC, 85%) with adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell neuroendocrine carcinoma (LCNEC) being the most common morphological subtypes [2]. This purely morphological classification has been challenged in the past decades, as AC can be further subdivided into distinct molecular subtypes. Since the discovery of EGFR mutations in 2004, several other oncogenic driver alterations have been identified This led to the development of very effective new targeted agents, and to a relevant progress in the treatment of oncogene-addicted NSCLC. The present review provides an overview on targeted therapy options in advanced and metastatic NSCLC with oncogenic driver alterations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
